VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
HAE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
HAEHaemonetics Corporation
$106.82$4.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. HAE
  4. Financial Ratios

Haemonetics Corporation (HAE) Financial Ratios

Latest Ratios: P/E Ratio 52.1x · EV/EBITDA 14.7x · ROE 12.0%. (1997–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

HAE Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$4.9B$2.6B$3.2B$4.4B$4.3B$3.2B$5.7B$5.2B$4.6B$3.9B$2.1B
Enterprise Value$5.8B$3.5B$4.1B$5.0B$4.7B$3.8B$6.3B$5.5B$4.8B$4.0B$2.3B
P/E Ratio →52.1126.3619.0937.2736.9475.2671.6267.3484.1286.07—
P/S Ratio3.641.922.363.353.643.276.545.224.794.332.36
P/B Ratio6.353.213.914.575.204.337.788.806.935.202.83
P/FCF18.649.8322.5038.0026.1342.8679.3447.18114.8726.8925.00
P/OCF16.568.7317.6424.1415.5818.8552.3332.6429.0817.7613.09

P/E links to full P/E history page with 30-year chart

HAE EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—2.653.033.834.053.797.215.534.974.412.56
EV / EBITDA14.698.9112.4719.7919.6722.5236.0827.9724.9427.4235.04
EV / EBIT24.1722.5716.6924.2528.3335.8362.7432.9957.6062.1557.77
EV / FCF—13.5928.9543.4429.0849.7487.5149.96119.3527.4027.10

HAE Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin55.7%55.7%57.2%54.4%53.3%53.4%49.2%49.4%43.2%45.6%42.7%
Operating Margin18.1%18.1%16.3%12.6%13.4%8.1%10.3%10.5%8.6%6.2%-2.2%
Net Profit Margin7.3%7.3%12.3%9.0%9.9%4.4%9.1%7.7%5.7%5.0%-3.0%

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE12.0%12.0%18.8%13.2%14.7%5.9%12.1%12.2%7.7%6.1%-3.6%
ROA4.0%4.0%7.2%5.7%6.1%2.4%5.1%6.0%4.4%3.7%-2.1%
ROIC10.3%10.3%10.0%8.6%9.1%4.7%6.1%8.9%7.5%4.8%-1.5%
ROCE12.1%12.1%11.8%9.2%10.1%5.4%7.0%10.2%8.8%6.0%-1.8%

HAE Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity1.541.541.490.840.941.041.060.750.520.340.43
Debt / EBITDA3.083.083.703.193.184.674.472.261.811.744.87
Net Debt / Equity—1.231.120.660.590.700.800.520.270.100.24
Net Debt / EBITDA2.472.472.782.482.003.123.371.560.940.512.71
Debt / FCF—3.766.445.452.966.888.172.784.480.512.09
Interest Coverage5.465.4625.3515.8911.436.145.9510.238.4314.184.84

HAE Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio2.952.951.622.563.061.712.742.202.441.352.42
Quick Ratio1.871.870.991.502.031.051.461.211.620.941.58
Cash Ratio0.870.870.530.601.130.590.760.500.720.470.66
Asset Turnover—0.560.560.600.600.530.480.780.760.730.72
Inventory Turnover1.931.931.591.882.101.581.371.852.833.062.87
Days Sales Outstanding—59.3354.3657.6055.9558.5753.4961.0069.8061.0662.89

HAE Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield1.9%3.8%5.2%2.7%2.7%1.3%1.4%1.5%1.2%1.2%—
FCF Yield5.4%10.2%4.4%2.6%3.8%2.3%1.3%2.1%0.9%3.7%4.0%
Buyback Yield3.6%6.8%7.0%0.0%1.8%0.0%0.0%3.4%3.5%2.6%0.0%
Total Shareholder Yield3.6%6.8%7.0%0.0%1.8%0.0%0.0%3.4%3.5%2.6%0.0%
Shares Outstanding—$47M$51M$51M$51M$51M$51M$52M$53M$54M$52M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Persistent TTM revenue decline

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q1)

Margin Recovery Masks Underlying Volatility

Gross margin expanded to 59.8% in Q1 FY2027 from 53.3% a year earlier, yet net margin swung from -5.8% to 9.7% sequentially, per reported financials, indicating earnings quality remains uneven.

The gross margin improvement suggests pricing power and cost control in production, but the wide swings in net margin—from -5.8% in Q4 FY2026 to 9.7% in Q1 FY2027—point to non-operating items or one-time charges distorting bottom-line profitability. Operating margin at 16.9% in Q1 FY2027 is the highest in five quarters, yet SG&A remains elevated at 35% of revenue, implying that margin expansion is not yet broad-based. Investors should monitor whether the gross margin gains can be sustained as input costs and product mix evolve.

Return on Capital Remains Subdued

ROIC has hovered between 1.4% and 2.9% over the past ten quarters, with Q1 FY2027 at 2.4%, according to quarterly data, suggesting the company is not yet compounding returns on invested capital at an attractive rate.

Despite a strong gross margin, ROIC remains low, indicating that the capital base—bolstered by acquisitions and placed equipment—is not generating commensurate operating profits. The slight uptick from 1.4% in 2024Q4 to 2.4% in Q1 FY2027 is encouraging but still below the cost of capital, implying value creation is limited. The driver appears to be asset efficiency, as asset turnover has been flat at 0.14, rather than margin expansion, which suggests that the business model requires heavy asset investment to generate sales.

Working Capital Cycle Lengthens on Inventory

Cash conversion cycle extended to 227 days in Q1 FY2027 from 202 days in 2024Q4, driven by inventory days rising to 204, as per quarterly data, indicating growing working capital absorption.

The lengthening CCC is primarily due to a sharp increase in days inventory outstanding (DIO) from 185 to 204 over the same period, while days sales outstanding (DSO) remained stable around 56-58 days. This suggests that inventory is building, possibly in anticipation of demand or due to supply chain issues, which ties up cash and reduces efficiency. The company's ability to manage inventory levels will be critical, as prolonged high DIO could pressure free cash flow and signal demand softness.

Leverage Creeps Higher on Acquisition Debt

Debt-to-equity rose from 0.84 in 2024Q4 to 1.40 in Q1 FY2027, with interest coverage at 4.81, per balance sheet data, indicating increased financial risk but still manageable debt service.

The rise in leverage is likely tied to the OpSens acquisition, as total debt increased to $1.2B while equity remained relatively stable. Interest coverage of 4.81 in Q1 FY2027 is adequate but down from 8.55 in 2025Q2, reflecting higher debt and volatile operating income. The negative interest coverage in Q4 FY2026 (-4.28) highlights the risk of earnings volatility, but the current quarter's recovery suggests the company can service its debt under normal conditions. Investors should monitor whether cash flow generation can keep pace with debt obligations, especially if growth initiatives require further capital.

Liquidity Buffer Strengthens but Inventory Heavy

Current ratio improved to 3.08 in Q1 FY2027 from 2.56 in 2024Q4, while quick ratio rose to 1.91, per quarterly data, indicating a solid short-term liquidity position despite inventory build.

The current ratio of 3.08 suggests ample coverage of short-term liabilities, but the quick ratio of 1.91 indicates that a significant portion of current assets is tied up in inventory, which may be less liquid in a downturn. The improvement in liquidity ratios is partly due to a rise in cash to $223.4M, but the inventory build (DIO at 204 days) could become a drag if demand falters. Under severe stress, the company appears able to meet obligations, but the reliance on inventory conversion warrants monitoring.

Misapplied Metric: P/E on Volatile Earnings

The trailing P/E of 44.29 is misleading given net margin swings from -5.8% to 17.5% over the past year, as per reported figures, so investors should focus on EV/EBITDA or normalized earnings.

The P/E ratio is distorted by the volatile net income, which swung from a loss in Q4 FY2026 to a profit in Q1 FY2027, making the trailing multiple unreliable. EV/EBITDA of 12.86 provides a more stable valuation metric, as it is less affected by non-operating items and tax adjustments. Additionally, the company's razor-and-blade model with placed equipment and software subscriptions suggests that free cash flow or EBITDA may better reflect underlying earning power than net income. Investors should adjust for one-time items and the impact of acquisitions to derive a normalized earnings figure for valuation.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open HAE Terminal

HAE Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HAE — Frequently Asked Questions

Quick answers to the most common questions about buying HAE stock.

What is Haemonetics Corporation's P/E ratio?

Haemonetics Corporation's current P/E ratio is 52.1x. The historical average is 45.1x. This places it at the 70th percentile of its historical range.

What is Haemonetics Corporation's EV/EBITDA?

Haemonetics Corporation's current EV/EBITDA is 14.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.

What is Haemonetics Corporation's ROE?

Haemonetics Corporation's return on equity (ROE) is 12.0%. The historical average is 8.7%.

Is HAE stock overvalued?

Based on historical data, Haemonetics Corporation is trading at a P/E of 52.1x. This is at the 70th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Haemonetics Corporation's profit margins?

Haemonetics Corporation has 55.7% gross margin and 18.1% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Haemonetics Corporation have?

Haemonetics Corporation's Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.